Results 51 to 60 of about 36,269 (231)

Cancer-associated fibroblasts secrete FGF5 to inhibit ferroptosis to decrease cisplatin sensitivity in nasopharyngeal carcinoma through binding to FGFR2

Cell Death and Disease
Cisplatin (DDP)-based chemoradiotherapy is one of the standard treatments for nasopharyngeal carcinoma (NPC). However, the sensitivity and side effects of DDP to patients remain major obstacles for NPC treatment.
Feng Liu, Ling Tang, Huai Liu, Yanzhu Chen, Tengfei Xiao, Wan-Yi Gu, Hongmin Yang, Hui Wang, Pan Chen   +8 more
semanticscholar   +1 more source

Noninvasive Detection of Polyclonal Acquired Resistance to FGFR Inhibition in Patients With Cholangiocarcinoma Harboring FGFR2 Alterations

JCO Precision Oncology, 2021
PURPOSE Fibroblast growth factor receptor (FGFR) 2 alterations, present in 5%-15% of intrahepatic cholangiocarcinomas (IHC), are targets of FGFR-directed therapies. Acquired resistance is common among patients who respond.
A. Varghese, J. Patel, Y. Janjigian, Fanli Meng, S. D. Selcuklu, G. Iyer, B. Houck-Loomis, J. Harding, E. O’Reilly, G. Abou-Alfa, M. Lowery, M. Berger   +11 more
semanticscholar   +1 more source

Clinical Value of Liquid Biopsy in Patients with FGFR2 Fusion–Positive Cholangiocarcinoma During Targeted Therapy

Clinical Cancer Research
Purpose: FGFR2 fusions occur in 10% to 15% of patients with intrahepatic cholangiocarcinoma (iCCA), potentially benefiting from FGFR inhibitors (FGFRi). We aimed to assess the feasibility of detecting FGFR2 fusions in plasma and explore plasma biomarkers
Alberto Gonzalez-Medina, Maria Vila-Casadesús, Marina Gómez-Rey, C. Fabregat-Franco, Alexandre Sierra, Tian V. Tian, F. Castet, Gloria Castillo, J. Matito, P. Martinez, J. Miquel, P. Nuciforo, R. Pérez-López, T. Macarulla, A. Vivancos   +14 more
semanticscholar   +1 more source

Clinical application of a double-modified sulfated bacterial cellulose scaffold material loaded with FGFR2-modified adipose-derived stem cells in urethral reconstruction

Stem cell research & therapeutics, 2022
Urethral stricture and reconstruction are one of the thorny difficult problems in the field of urology. The continuous development of tissue engineering and biomaterials has given new therapeutic thinking to this problem.
Zhenpeng Zhu, Jiayu Yang, X. Ji, Zicheng Wang, Cheng-xiang Dai, Su-ke Li, Xuesong Li, Yajie Xie, Yudong Zheng, Jian Lin, Liqun Zhou   +10 more
semanticscholar   +1 more source

Understanding and Overcoming Resistance to Selective FGFR Inhibitors across FGFR2-Driven Malignancies

Clinical Cancer Research
Purpose: Understanding resistance to selective FGFR inhibitors is crucial to improve the clinical outcomes of patients with FGFR2-driven malignancies.
F. Facchinetti, Y. Loriot, F. Brayé, D. Vasseur, R. Bahleda, L. Bigot, Rémy Barbé, Catline Nobre, D. Combarel, S. Michiels, A. Italiano, C. Smolenschi, L. Tselikas, J. Scoazec, Santiago Ponce-Aix, Benjamin Besse, F. André, K. Olaussen, A. Hollebecque, L. Friboulet   +19 more
semanticscholar   +1 more source

Effect of FGFR2 Alterations on Overall and Progression-Free Survival in Patients Receiving Systemic Therapy for Intrahepatic Cholangiocarcinoma

Targeted oncology, 2022
First-line standard-of-care therapy for advanced cholangiocarcinoma is gemcitabine plus cisplatin; there is no established second-line systemic therapy. Fibroblast growth factor receptor (FGFR)-2 fusions/rearrangements can be oncogenic drivers, occurring
G. Abou-Alfa, K. Bibeau, N. Schultz, Amin Yaqubie, Brittanie M Millang, H. Ren, L. Féliz   +6 more
semanticscholar   +1 more source

Influence of FGF4 and BMP4 on FGFR2 dynamics during the segregation of epiblast and primitive endoderm cells in the pre-implantation mouse embryo.

PLoS ONE, 2023
Specification of the epiblast (EPI) and primitive endoderm (PE) in the mouse embryo involves fibroblast growth factor (FGF) signaling through the RAS/MAP kinase pathway.
Marcelo D Goissis, Brian Bradshaw, Eszter Posfai, Janet Rossant   +3 more
doaj   +1 more source

Clinical Developments and Challenges in Treating FGFR2-Driven Gastric Cancer

Biomedicines
Recent advances in the treatment of gastric cancer (GC) with chemotherapy, immunotherapy, anti-angiogenic therapy and targeted therapies have yielded some improvement in survival outcomes; however, metastatic GC remains a lethal malignancy and amongst ...
David K. Lau, Jack P. Collin, J. Mariadason   +2 more
semanticscholar   +1 more source

FIGHT-302: first-line pemigatinib vs gemcitabine plus cisplatin for advanced cholangiocarcinoma with FGFR2 rearrangements

Future Oncology, 2020
FGFR2 rearrangements resulting in dysregulated signaling are drivers of cholangiocarcinoma (CCA) tumorigenesis, and occur almost exclusively in intrahepatic CCA.
T. Bekaii-Saab, J. Valle, E. Cutsem, L. Rimassa, J. Furuse, T. Ioka, D. Melisi, T. Macarulla, J. Bridgewater, H. Wasan, M. Borad, G. Abou-Alfa, P. Jiang, C. Lihou, H. Zhen, E. Asatiani, L. Féliz, A. Vogel   +17 more
semanticscholar   +1 more source

Phenotypic and genotypic characterization of single circulating tumor cells in the follow‐up of high‐grade serous ovarian cancer

Molecular Oncology, EarlyView.
Single circulating tumor cells (sCTCs) from high‐grade serous ovarian cancer patients were enriched, imaged, and genomically profiled using WGA and NGS at different time points during treatment. sCTCs revealed enrichment of alterations in Chromosomes 2, 7, and 12 as well as persistent or emerging oncogenic CNAs, supporting sCTC identity.
Carolin Salmon, Rui P. L. Neves, Nikolas H. Stoecklein, Sven‐Thorsten Liffers, Jens Siveke, Jan D. Kuhlmann, Pauline Wimberger, Paul Buderath, Rainer Kimmig, Sabine Kasimir‐Bauer   +9 more
wiley   +1 more source